Attard Azizah, Wakelam John, Broyd Josephine, Taylor David, Hafferty Jonathan
Pharmacy Department, West London NHS Trust, 1 Armstrong Way, Southall, London UB1 3EU, UK.
Pharmacy Department, West London NHS Trust, London, UK.
Ther Adv Psychopharmacol. 2022 Jul 18;12:20451253221113093. doi: 10.1177/20451253221113093. eCollection 2022.
Olanzapine pamoate has been shown to be an effective second-generation long-acting injection. Its popularity has possibly been adversely affected by the rare incidence of post-injection syndrome (PIS) and the associated requirement to monitor for 3 h after each injection.
This study aimed to collect and present data on the use of olanzapine long-acting injection (OLAI) over a 10-year period in a high-security forensic hospital in South East England.
This was a non-interventional retrospective study collecting information from anonymised electronic patient and prescription records. As per hospital Trust guidelines, patient consent to access of hospital records was presumed unless explicitly withdrawn.
All patients prescribed OLAI between the years 2009 and 2019 were identified. Data collected included date that OLAI was started, stopped, dose range, side effects and concomitant medication.
Of 88 patients who were started OLAI, 45 (51%) continued at month 24. At 60 months, 22 of 70 (31%) patients for whom data were available continued with OLAI. Over 60% of continuers were on higher than recommended doses. Of almost 5000 injections administered, there was 1 episode of PIS.
OLAI is an effective treatment for schizophrenia and schizoaffective disorder, especially when used in patients have been able to tolerate the drug and were stabilised on it for 24 months. In over half the patients who continued OLAI, the doses were higher than that recommended by the manufacturer. The incidence of PIS in this study was very low in comparison with other studies.
奥氮平棕榈酸酯已被证明是一种有效的第二代长效注射剂。其受欢迎程度可能受到注射后综合征（PIS）罕见发生率以及每次注射后需监测3小时这一相关要求的不利影响。
本研究旨在收集并呈现英格兰东南部一家高度戒备的法医医院在10年期间使用奥氮平长效注射剂（OLAI）的数据。
这是一项非干预性回顾性研究，从匿名的电子患者和处方记录中收集信息。根据医院信托指南，除非患者明确撤回同意，否则假定患者同意获取医院记录。
确定2009年至2019年间所有开具OLAI处方的患者。收集的数据包括开始使用、停止使用OLAI的日期、剂量范围、副作用和伴随用药情况。
在开始使用OLAI的88例患者中，45例（51%）在第24个月时仍在继续使用。在60个月时，70例有可用数据的患者中有22例（31%）继续使用OLAI。超过60%的继续使用者使用的剂量高于推荐剂量。在近5000次注射中，有1例发生PIS。
OLAI是治疗精神分裂症和分裂情感性障碍的有效方法，尤其是用于能够耐受该药物并已在其上稳定24个月的患者。在继续使用OLAI的患者中，超过一半的患者使用的剂量高于制造商推荐的剂量。与其他研究相比，本研究中PIS的发生率非常低。
2049。
